BioPharmSignal logoBioPharmSignal

Biotech News

Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale

Supernus (SUPN)SupernusCompany update

Combines highly complementary businesses, with a diversified portfolio of CNS medicines totaling approximately $2.2 billion in combined annual revenues Enhanced financial position and free cash flow generation enabling greater financial flexibility to pursue internal and external growth

Related news

SUPNSupernus2026-07-22 21:05 EST

Supernus Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 4, 2026

SUPNSupernus2026-05-27 20:30 EST

Supernus Pharmaceuticals to Participate in June Investor Conferences

TNXPTonix Pharmaceuticals2026-08-10 11:00 EST

Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights

ABOSAcumen Pharmaceuticals2026-07-07 11:30 EST

Acumen Pharmaceuticals to Present Data on Enhanced Brain Delivery™ (EBD™) Technology and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026

ABOSAcumen Pharmaceuticals2026-08-12 11:00 EST

Acumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Highlights

XENEXenon2026-07-31 20:01 EST

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

TNXPTonix Pharmaceuticals2026-07-13 11:00 EST

Tonix Pharmaceuticals Announces Major Managed Medicare Payer Agreement for TONMYA®

ANNXAnnexon, Inc.2026-08-12 10:00 EST

Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study

ANNXAnnexon, Inc.2026-08-10 20:05 EST

Annexon Appoints Renowned Retinal Surgeon and Biotechnology Entrepreneur Mark S. Blumenkranz, M.D., M.M.S. to its Board of Directors

HRMYHarmony Biosciences2026-07-16 12:30 EST

Harmony Biosciences Preannounces Record Quarterly Revenue for Q2 2026, Reaffirms Full-Year 2026 Revenue Guidance, and Announces CFO Transition

View all latest news

Supernus

CNS Commercial Portfolio Supernus Pharmaceuticals develops and commercializes treatments for central nervous system disorders. Its marketed portfolio spans attention-deficit hyperactivity disorder, Parkinson’s disease, postpartum depression, epilepsy, migraine, cervical dystonia and chronic sialorrhea. Growth Products The company’s...

Recent company news

SUPNSupernus2026-08-03 10:35 EST

Supernus Announces Second Quarter 2026 Financial Results

SUPNSupernus2026-08-03 10:30 EST

Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale

SUPNSupernus2026-07-22 21:05 EST

Supernus Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 4, 2026

SUPNSupernus2026-07-14 12:30 EST

Supernus Celebrates Five-Year Anniversary of Qelbree® FDA Approval, Continuing to Deliver on Real-World Experience in ADHD

SUPNSupernus2026-05-27 20:30 EST

Supernus Pharmaceuticals to Participate in June Investor Conferences

Stock data

Close
45.85 USD
Market cap
2.56B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States